Learning a Complete Image Indexing Pipeline

To work at scale, a complete image indexing system comprises two components: An inverted file index to restrict the actual search to only a subset that should contain most of the items relevant to the query; An approximate distance computation mechanism to rapidly scan these lists. While supervised deep learning has recently enabled improvements to the latter, the former continues to be based on unsupervised clustering in the literature. In this work, we propose a first system that learns both components within a unifying neural framework of structured binary encoding

Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways-6

or 72 hours. The cell number was recorded at each time point. Diamond (♦), control; Square (■), 0.1 μM; Triangle (), 0.5 μM; Dot (●); 5.0 μM. (B). PHI induces G1 growth arrest. The myeloma cells were cultured with 0.5 μM of PHI for 48 or 96 hours. The cellular DNA content was determined by flow cytometry. Values are means +/- SD from 3 independent experiments. Open bar, G1 phase; Black bar, G2M phase; Grid bar, S phase.<p><b>Copyright information:</b></p><p>Taken from "Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways"</p><p>http://www.jhoonline.org/content/1/1/6</p><p>Journal of Hematology and Oncology 2008;1():6-6.</p><p>Published online 9 Jun 2008</p><p>PMCID:PMC2438442.</p><p></p

Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways-5

measured by flowcytometry as described in the Material and Methods. The shift-down of fluorescence from Red to Green indicates the collapse of mitochondrial membrane potential. CCCP was used as a positive control for the disruption of mitochondrial membrane potential. The percent of cells with the disruption of mitochondrial membrane potential was indicated.<p><b>Copyright information:</b></p><p>Taken from "Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways"</p><p>http://www.jhoonline.org/content/1/1/6</p><p>Journal of Hematology and Oncology 2008;1():6-6.</p><p>Published online 9 Jun 2008</p><p>PMCID:PMC2438442.</p><p></p

Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways-4

Diamond (♦), control; Square (■), 0.1 μM; Triangle (), 5 μM; Cross (x), 10 μM. (B). Percent inhibition of VEGF production as compared with the control culture was calculated from the above experiments. Values are means +/- SD from 3 independent experiments. Open bar, 24 hours; Black bar, 48 hours.<p><b>Copyright information:</b></p><p>Taken from "Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways"</p><p>http://www.jhoonline.org/content/1/1/6</p><p>Journal of Hematology and Oncology 2008;1():6-6.</p><p>Published online 9 Jun 2008</p><p>PMCID:PMC2438442.</p><p></p

Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study

Recombinant human TPO (rhTPO) is effective for refractory/relapsed primary immune thrombocytopenia (ITP), but optimal dosing regimen remains elusive. In this multicenter, randomized, controlled trial, a total of 282 adult ITP patients (mean age 47.3 years; 82 men) with a platelet count ≤30 × 109/L or >30 × 109/L with active bleeding randomly received a once daily (QD) subcutaneous injection of 7500 U (n = 64) or 15000 U rhTPO for 14 injections, or 15000 U or 30000 U rhTPO once every other day (QOD) for 7 injections. The primary outcomes included change from baseline in platelet count and total response rate (TRR) on day 14. On day 14, the median increase of platelet count from baseline was the highest in the 15000-U QD group (167.5 × 109/L, interquartile range [IQR] 23.0–295.0 × 109/L), followed by the 30000-U QOD group (57.5 × 109/L, IQR 9.0–190.0 × 109/L) (ANCOVA P P = .266 with baseline count as a covariate). The TRR on day 14 was also the highest in the 15000-U QD group (63.2%), followed by the 30000-U QOD group (59.7%). The rate of grade 3 and above adverse events did not differ among the four groups. There were no new safety concerns. All 4 regimens are safe and well-tolerated. The 30000-U QOD regimen is practically indistinguishable in efficacy to the 15000-U QD regimen. What is the context?Relative thrombopoietin deficiency is implicated in primary immune thrombocytopenia (ITP), which is characterized by increased platelet destruction and impaired megakaryopoiesis.Patients who are innately unresponsive to or have relapsed after glucocorticoid treatment have limited treatment options.Recombinant human thrombopoietin (rhTPO) improves treatment response of primary ITP patients when added to high-dose dexamethasone. Relative thrombopoietin deficiency is implicated in primary immune thrombocytopenia (ITP), which is characterized by increased platelet destruction and impaired megakaryopoiesis. Patients who are innately unresponsive to or have relapsed after glucocorticoid treatment have limited treatment options. Recombinant human thrombopoietin (rhTPO) improves treatment response of primary ITP patients when added to high-dose dexamethasone. What is new?This trial sought to identify an optimal dosing regimen of rhTPO for patients who had failed or relapsed after glucocorticoid therapy.Of the 4 regimens, once daily 15000 U rhTPO for 14 injections yielded the greatest median increase in platelet count (167.5 × 109/L) from baseline and attained the highest total response rate on day 14 (63.2%).30000 U rhTPO once every other day for 7 injections was effective in rapidly increasing platelet counts in the first 7 days.All 4 regimens were safe and well-tolerated. This trial sought to identify an optimal dosing regimen of rhTPO for patients who had failed or relapsed after glucocorticoid therapy. Of the 4 regimens, once daily 15000 U rhTPO for 14 injections yielded the greatest median increase in platelet count (167.5 × 109/L) from baseline and attained the highest total response rate on day 14 (63.2%). 30000 U rhTPO once every other day for 7 injections was effective in rapidly increasing platelet counts in the first 7 days. All 4 regimens were safe and well-tolerated. What is the impact?The 30000 U rhTPO once every other day regimen may offer an effective and safe regimen with less frequent injections, but future trials with longer follow-up are needed. The 30000 U rhTPO once every other day regimen may offer an effective and safe regimen with less frequent injections, but future trials with longer follow-up are needed.</p